Novel therapeutic intervention for osteoporosis
AssigneeNational Centre for Cell Science
InventorsKanupriya Singh, Mohan Ramchandra Wani
Life of this patent
Estimating the term…
Abstract
The present invention discloses a novel therapeutic intervention for osteoporosis. The present invention discloses that Interleukin-3 (IL-3) can be utilized as a therapeutic intervention against osteoporosis and for regulating bone homeostasis. The present invention also provides a method for determining the pre-disposition of a subject for osteoporosis by measuring the RANKL/OPG level.
Claims13
A method of treating osteoporosis comprising administering to a mammal a therapeutically effective amount of interleukin 3 or a functional analogue thereof which retains the characteristics of interleukin 3.
A method with a predetermined level of predictability for assessing a risk of development of osteoporosis, pre-osteoporosis, or bone fracture in a subject comprising:
- i. determining the ratio between RANKL/OPG levels;
- ii. measuring a clinically significant alteration in the RANKL/OPG levels;
- and
- iii. assessing predisposition to osteoporosis, increased risk of developing osteoporosis, pre-osteoporosis, or bone fracture in the subject from step (ii).
An in-vitro method for elucidation of osteoclastogenesis and bone homeostasis modulation, comprising:
- i. isolating the osteoblasts;
- ii. assessing the effect of IL-3 on expression of stimulatory and inhibitory proteins in the osteoblasts obtained from step i) at both gene and protein levels;
- iii. assessing the of effect of IL-3 on total and membrane bound stimulatory protein RANKL in osteoblasts obtained from step ii) by flow cytometry and enzyme linked immunosorbent assay (ELISA);
- iv. assessing the role of IL-3 on expression of stimulatory and inhibitory proteins in vivo;
- v. isolating osteoclasts precursors;
- vi. co-culturing the osteoblasts and osteoclast precursors obtained from step i) and (v) with cytokine;
- and
- vii. studying the effect of IL-3 in osteoclasts obtained from step vi.
Use of Interleukin-3 in bone homeostasis modulation and for intervention in skeletal disorders.
Dependencies are inferred from the claim text.